Development of a xenograft @entity11 model in XXXX brain.

@entity19 @entity5 @entity36 @entity11 @entity35 @entity1779
Xenograft @entity1779 models have been developed in normal @entity19 by growing the @entity35 @entity36 in either adult or neonatal @entity19 brains. Using this @entity5 line it was possible to grow discrete @entity1779 in either CBA or AKR adult @entity19 or neonatal @entity19 . The size of the @entity5 mass and length of survival was directly related to the number of @entity5 cells injected and the time after implantation. To obtain localized @entity5 growth cells were suspended in a 1% agarose solution before implantation. Following injection of 10(6) cells into the frontal lobe of adult CBA or AKR @entity19 , discrete @entity5 masses greater than 4 mm in diameter were obtained in 90% of animals at 14 days, and the @entity5 in adult @entity19 occurred between 21 and 28 days after implantation. The @entity5 size following implantation of 10(6) cells was significantly greater than with 10(5) cells at 7 days (P less than 0.05) and at 14 and 21 days (P less than 0.01). Less than 60% of @entity19 of BALB/c, RIII, or C57 black strains developed @entity5 greater than 4 mm diameter at 14 days after intracerebral injection of 10(6) C6 cells. Using neonatal @entity19 it was found that when 10(5) cells were injected intracranially @entity5 greater than 4 mm in diameter developed in 14 of 15 animals within 2 weeks (CBA @entity19 ). Similar results were seen in the RIII, AKR, C57 black, and BALB/c strains. Longer growth periods resulted in @entity5 , up to 8 mm in diameter (6 of 10 animals at 20 days). The @entity5 in the neonatal animals were not as discrete as in the adult @entity19 , and @entity5 often spread to the meninges and into the lateral ventricles. The @entity5 harvested from the brain had a cloning efficiency of 1.2 +/- 0.4% (SD). A panel of monoclonal antibodies was raised to the @entity36 , and this was used to define clearly the margins of the @entity5 within the brain. The xenograft @entity19 models should prove useful for the study of the therapy of @entity11 .
